Press Releases
- Highlights Press Releases-Immunomic Therapeutics to receive upfront payment of $300 million plus 10 percent royalties from potential products for allergic diseases, including peanut allergy- -Immunomic Therapeutics to retain rights of LAMP-vax platformRead more
Immunomic Therapeutics, Inc. to Present at Skin Vaccination Summit in Switzerland
Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., Aug. 28, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces thatRead moreImmunomic Therapeutics, Inc. Taps Micronaut to Visually Demonstrate Its LAMP-vax Programs
Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., June 16, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces thatRead moreImmunomic Therapeutics, Inc. CEO, William Hearl, Ph.D. to Speak at 2015 BIO International Convention
Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., June 3, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces thatRead more- Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., May 13, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces thatRead more
Immunomic Therapeutics Names Louise Peltier as Vice President, Regulatory Affairs
Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., May 6, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces itRead moreImmunomic Therapeutics Appoints Eric Winzer as Chief Financial Officer
Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., May 4, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. (ITI), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces itRead more- Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., March 31, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces thatRead more
Immunomic Therapeutics To Present at BIO-Europe Annual Conference
Press ReleasesHershey, PA, & Rockville, MD – March 9, 2015 – Immunomic Therapeutics, Inc., (“ITI”) a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it willRead moreImmunomic Therapeutics, Inc. Appoints Vice President of Operations
Press ReleasesHERSHEY, PA & ROCKVILLE, MD (PRWEB) FEBRUARY 10, 2015 Immunomic Therapeutics, Inc. (ITI) announced today that Timothy Coleman Ph.D. has joined the company to further develop a comprehensive growth plan andRead more- Press ReleasesHERSHEY, Pa., Rockville, Md. and TOKYO, Jan. 29, 2015 /PRNewswire/ -- Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered intoRead more
Immunomic Therapeutics, Inc., To Present at Biotech Showcase™ 2015
Press ReleasesHERSHEY, PA AND SAN FRANCISCO, CA (PRWEB) JANUARY 09, 2015 Immunomic Therapeutics, Inc., (ITI), a pioneering vaccine company, announced today that Dr. William Hearl, the Company’s President and CEO, will beRead more